-
Mashup Score: 10CCR8 expectations - 26 day(s) ago
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays - 1 month(s) ago
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3AACR 2024 – Akeso impresses in stomach cancer - 1 month(s) ago
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3J&J speeds into new bladder cancer trial - 2 month(s) ago
The company takes another project from Taris into phase 3 as it chases a $5bn market.
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Time for Gilead to cut magrolimab loose - 3 month(s) ago
Another week, another magrolimab setback. The four remaining solid tumour trials of the Gilead anti-CD47 MAb that were formally still ongoing have now been placed on clinical hold by the FDA, according to a statement Gilead quietly slipped out last night. Last week the project’s key phase 3 AML trial Enhance-3 was discontinued, along with all work in haematology, after an increased risk of death…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Revolution in the next KRAS battleground - 3 month(s) ago
With Revolution Medicines initiating dosing in the first-in-human study of its KRAS G12D inhibitor RMC-9805, the industry pipeline now comprises six clinical-stage projects with this modality. If the KRAS G12C space, now featuring the approved drugs Lumakras from Amgen and Krazati from Mirati, fast became crowded, then that targeting KRAS G12D-driven tumours might follow suit, given that G12D is…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8The pullback from RET inhibition - 3 month(s) ago
Lilly’s disclosure today that it was discontinuing the next-generation RET inhibitor LOXO-260 points to the quiet biopharma exodus from this once-promising mechanism. On one hand Lilly’s Retevmo has grabbed the lion’s share of first-line RET-mutant NSCLC patients, with the Libretto-431 trial backing the registrational Libretto-001 study, an achievement that saw off one competitor: Roche pulled…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Bristol shows its alnuctamab hand - 3 month(s) ago
With two BCMA-targeting T-cell-engager bispecifics already boasting US accelerated approvals, and a third seeking a similar nod, how can others compete? Bristol Myers Squibb and AbbVie haven’t said they would pursue the accelerated pathway for alnuctamab and ABBV-383 respectively, and both are now in formal phase 3 trials. The unveiling of alnuctamab’s phase 3 Alumminate study has revealed that…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7ASCO-GI – Leap falters again - 4 month(s) ago
Leap Therapeutics, having already fallen last week on ASCO-GI abstract data, sank another 6% on Tuesday following more detailed results from the Defiance trial of its lead project, DKN-01. The uncontrolled first part of the study tested DKN-01 plus Avastin and chemo in second-line colorectal cancer; the concern was that, with around half of patients naive to Avastin, responses might have been…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3ASCO-GU preview: showdown for Exelixis - 4 month(s) ago
Among the abstract titles from ASCO’s upcoming Genitourinary Cancers Symposium, all of which are now available, one that stands out concerns the Contact-02 trial of Exelixis/Ipsen’s Cabometyx in second-line prostate cancer. That study was toplined as positive for progression-free survival last August, marking a rare success for the Cabometyx franchise beyond its blockbuster kidney cancer setting….
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
RT @JacobPlieth: Is CCR8 the new Claudin18.2? @ApexOnco analysis of an I-O mechanism that's quietly become hot: https://t.co/TzuGyiWRGM $CH…